Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Robert Parsons

Nurse Practitioner, Psychiatric/Mental Health Youngstown, OH Nurse Practitioner

NPI 1588625081 CMS profile 11050968

16 Colonial Dr, Youngstown, OH 44505

Open in the dashboard

General payments

$118,639

1,033 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Parsons of Youngstown, OH is reported in the CMS Open Payments database as having received $118,639 across 1,033 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $69,368 303
2024 General $14,454 143
2023 General $13,117 178
2022 General $14,815 203
2021 General $6,886 206

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Parsons
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Robert Parsons were reported at $69,368. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Robert Parsons Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $6,886 $166 $54–$482 $132
2022 $14,815 $195 $66–$559 $149
2023 $13,117 $233 $82–$673 $160
2024 $14,454 $236 $84–$688 $164
2025 $69,368 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. E.R. Squibb & Sons, L.L.C. $79,576 161 payments
  2. Alkermes, Inc. $27,064 120 payments
  3. AbbVie, Inc. $2,634 74 payments
  4. Otsuka America Pharmaceutical, Inc. $2,125 164 payments
  5. ITI, Inc. $1,644 117 payments
  6. Lundbeck LLC $1,298 134 payments
  7. Teva Pharmaceuticals USA, Inc. $705 46 payments
  8. Janssen Pharmaceuticals, Inc $655 37 payments
  9. Vanda Pharmaceuticals Inc. $591 47 payments
  10. Neurocrine Biosciences, Inc. $561 31 payments
  11. Other $1,785 102 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $72,605 44 payments
  2. Travel and Lodging $17,291 73 payments
  3. Food and Beverage $17,180 906 payments
  4. Consulting Fee $11,440 7 payments
  5. Education $123 3 payments
Products named General payments · program years 2021–2025
  1. COBENFY Neuroscience $59,977 124 payments
  2. LYBALVI Cns $25,412 106 payments
  3. LYBALVI Cns $17,736 57 payments
  4. LYBALVI Cns $17,608 48 payments
  5. LYBALVI Cns $17,608 48 payments
  6. ARISTADA Cns $9,457 72 payments
  7. ARISTADA Cns $9,457 72 payments
  8. ARISTADA Cns $9,329 63 payments
  9. ARISTADA Cns $9,329 63 payments
  10. COBENFY Psychiatry/Psychology $6,577 14 payments
  11. Other $16,330 943 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

3,986

Median for Nurse Practitioner: 389

Drug cost

$1,003,273

Median for Nurse Practitioner: $21,885

Branded share of claims

27.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 27 $208,223
Austedo Xr Deutetrabenazine Brand 21 $169,083
Austedo Deutetrabenazine Brand 20 $126,467
Caplyta Lumateperone Tosylate Brand 60 $100,479
Invega Sustenna Paliperidone Palmitate Brand 29 $93,101
Rexulti Brexpiprazole Brand 45 $68,528
Vraylar Cariprazine Hcl Brand 42 $60,860
Trintellix Vortioxetine Hydrobromide Brand 105 $50,322
Fetzima Levomilnacipran Hcl Brand 48 $24,522
Auvelity Dextromethorphan Hbr/Bupropion Brand 16 $18,311

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$8,739

Medicare's payments for the services billed

Medicare patients

37

Average age 55

Services billed

142

22 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 62%
High blood pressure 46%
Arthritis 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COBENFY
  • E.R. Squibb & Sons, L.L.C. $6,577
$6,577 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $161
  • Lundbeck LLC $140
$302 45 —
ARISTADA
  • Alkermes, Inc. $240
$240 — —
ABILIFY MAINTENA
  • Lundbeck LLC $115
  • Otsuka America Pharmaceutical, Inc. $83
$199 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $160
$160 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

1,033 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record